The Arora Report

March 8, 2017

TRUMP’S ‘OBAMACARE LITE’ PRESENTS OPPORTUNITIES AND PERILS FOR INVESTORS $XBI $MDT $BSX $EW $CYH $THC $PFE $JNJ $MRK $BMY $TEVA $MYL

Republicans have finally produced a detailed plan to repeal and replace the Affordable Care Act, also known as Obamacare.

Setting aside politics and viewing the plan neutrally, two things jump out. First, the House Republicans’ plan keeps the basic framework of Obamacare. No wonder some are calling it “Obamacare Lite.” Second, the cost is unknown, and therefore it’s difficult to know how it will be paid for. Also unknown: the number of people affected.

Other details: The individual mandate to buy insurance would be replaced with penalties that insurance companies can impose; subsidies would be replaced with refundable tax credits; taxes that supported Obamacare would be repealed; more responsibility would be given to the states; and the mandate to offer insurance irrespective of pre-existing conditions would remain.… Please click here or the title below to read more.

March 8, 2017

UPDATE ON RITE AID $RAD $WBA

UPDATE ON RITE AID $RAD $WBA This post was just published on ZYX Buy Change Alert.

Profits have been taken on RAD on all but 10% of the full core position size. There is speculation that FTC is not planning on making a quick decision on RAD buyout by WBA. Please understand that this is just speculation and not authoritative. RAD buyout can still happen at $7 per share although the risks are high.

The stock has dipped into the stop zone. We are lowering the stop zone on the remaining 10% position to $4.38 to $4.43 for those still holding. If holding a larger quantity, consider reducing the quantity on a bounce.

… Please click here or the title below to read more.

March 8, 2017

UPDATE ON BIOTECH BEAR ETF LABD FOR AGGRESSIVE INVESTORS ONLY $LABD

This post was just published on ZYX Buy Change Alert.

Please see the Morning Capsule for Trump Cummings meeting. Trump also stated that he is going to curb high drug prices in his address before the Congress. The market does not believe Trump and they keep on running pharmaceutical and biotech stocks on the belief that Trump will not succeed and drug prices will continue to go up.

This inverse ETF will go up if biotech and drug stocks fall. This ETF is leveraged and can move in a wide range. For this reason, consider reducing the recommended position size if it does not suit your risk profile and also if you are not holding significant long positions.

… Please click here or the title below to read more.

March 8, 2017